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Background: Mucopolysaccharidosis type I (MPSI) is caused by a deficiency in alpha-L iduronidase (IDUA), which
leads to lysosomal accumulation of the glycosaminoglycans (GAGs) dermatan and heparan sulfate. While the
currently available therapies have good systemic effects, they only minimally affect the neurodegenerative process.
Based on the neuroprotective and tissue regenerative properties of mesenchymal stem cells (MSCs), we
hypothesized that the administration of MSCs transduced with a murine leukemia virus (MLV) vector expressing
IDUA to IDUA KO mouse brains could reduce GAG deposition in the brain and, as a result, improve
neurofunctionality, as measured by exploratory activity.
Methods: MSCs infected with an MLV vector encoding IDUA were injected into the left ventricle of the brain of 12- or
25-month-old IDUA KO mice. The behavior of the treated mice in the elevated plus maze and open field tests was
observed for 1 to 2 months. Following these observations, the brains were removed for biochemical and histological
analyses.
Results: After 1 or 2 months of observation, the presence of the transgene in the brain tissue of almost all of the
treated mice was confirmed using PCR, and a significant reduction in GAG deposition was observed. This reduction was
directly reflected in an improvement in exploratory activity in the open field and the elevated plus maze tests. Despite
these behavioral improvements and the reduction in GAG deposition, IDUA activity was undetectable in these samples.
Overall, these results indicate that while the initial level of IDUA was not sustainable for a month, it was enough to
reduce and maintain low GAG deposition and improve the exploratory activity for months.
Conclusions: These data show that gene therapy, via the direct injection of IDUA-expressing MSCs into the brain, is an
effective way to treat neurodegeneration in MPSI mice.
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The disruption of lysosomal activity during cellular
metabolism results in an accumulation of glycosamino-
glycans (GAGs), which leads to a group of inherited
diseases known as lysosomal storage disorders (LSDs).
Mucopolysaccharidosis I (MPSI) is a LSD in which two
GAGs, dermatan and heparan sulfate, accumulate due
to a deficiency in alpha-L iduronidase (IDUA - EC 3.2.1.76).
The frequency of MPSI is 1 in 100,000 live births, and it
presents as a syndrome with one of three phenotypes,
Hurler (OMIM #607014), Hurler-Scheie (OMIM #607015)
or Scheie (OMIM # 607016). Recently, it has been sug-
gested that patients with MPSI should be classified into two
case types, attenuated (Hurler-Scheie and Scheie) and se-
vere (Hurler) [1]. MPSI patients develop splenomegaly,
bone and articular diseases and cardiorespiratory malfunc-
tions, among other problems. Hurler syndrome also results
in progressive and irreversible neurodegeneration, which
leads to death in early childhood [2].
Two types of treatment are currently available for
MPSI. The first option is bone marrow or stem cell
transplantation, which is efficient but limited by the
scarcity of compatible donors, the high mortality rate of
the procedure itself and the high financial cost. The sec-
ond alternative is enzyme replacement therapy (ERT),
which is effective in decreasing the hepatosplenomegaly
and improving articular movement. However, neither
transplantation nor ERT have prevented neurodegen-
eration [3]. Although preclinical studies have shown
that the enzyme can reach the central nervous system
(CNS) and provide therapeutic benefits [4] following a
high-dose infusion, these levels are not attainable at the
clinical level because more frequent infusions and
higher amounts of enzyme would be necessary. There-
fore, even the initiation of ERT early in childhood will
not result in significant benefits to the CNS, despite an
improvement in the visceral disease. In addition, MPSI
syndrome is not routinely diagnosed in newborns, and
most of the affected children are diagnosed much later
in life [3]. These observations necessitate the develop-
ment of alternative procedures aimed specifically at
treating the CNS.
Intravenous gene transfer into the brain of animals
with LSD via viral vectors is feasible in neonates, as has
been demonstrated with adenovirus-associated viral
(AAV) vectors, lentiviral vectors and retroviral vectors
[5-8]. In adult MPSI mice, however, the systemic injec-
tion of AAV and MLV (murine leukemia viral vector) has
been shown to result in a significant serum enzyme level,
but very low enzymatic activity has been detected in the
brain [6,8-11]. Importantly, a significant improvement in
the neurological abnormalities, as demonstrated using
behavioral tests, was only observed after neonatal viral
gene transfer in a murine MPSI model [5]. However, thebest way to reduce GAG accumulation in the brain
appears to be through the administration of AAV vectors
locally, even though this procedure is riskier and more
complicated in clinical trials [9,12].
To date, no gene therapy studies have examined the effi-
cacy of treating adult mice at different stages of disease,
which is a more appropriate model if we want to translate
the therapies into clinical trials. In few month-old MPSI
mice, a progressive decline in behavior is observed [12]
due to an accumulation of GAG deposits in the brain.
How GAG deposits affect neurocognition remains unclear,
even in patients [1]. Thus, it will be of great importance to
include behavioral tests that accurately reflect the changes
in GAG deposition, especially in brain gene therapy stud-
ies for MPSI. Behavioral tests have already been performed
in other types of MPS and show a good correlation with
changes in GAG deposition [7,13-16].
Mesenchymal stem cells (MSCs) have the potential to
differentiate into various cell types of mesenchymal ori-
gin, such as osteoblasts, chondrocytes and adipocytes
[17,18]. Additionally, recent work has demonstrated
that MSC can differentiate into neural cells in vitro and
in vivo [19,20]. A therapeutic effect from MSCs in an
injured brain has been observed in several animal mod-
els and clinical trials [21,22]. The benefits of MSC ther-
apy seems to stem from the role of MSCs in
neuroprotection, the promotion of tissue regeneration,
the induction of growth factor and cytokine expression
and vascularization. MSC-based therapy has also been
used in mice with MPS VII [23].
Based on the characteristics of MSCs and the need to
provide additional neurotrophic factors to mice with MPSI
in situ, we hypothesized that MSCs modified to express
IDUA delivered directly into the brain ventricles of mice
with MPSI would produce a synergistic therapeutic effect,
especially in adult animals. To validate our hypothesis,
adult mice with MPSI were used in our gene therapy study
for evaluating locomotor and exploratory behavior func-
tions in addition to molecular analyses.Materials and methods
IDUA −/− mice
IDUA −/− (KO) mice were generated via the targeted
disruption of the IDUA gene [23] (kindly provided by
Dr. Elizabeth Neufeld, UCLA, Los Angeles, CA, USA)
and maintained by breeding heterozygous animals. The
Research Ethics Committee of the Federal University of
São Paulo approved all of the conditions and experimen-
tal protocols (approval number CEP 1201/07). In our
experiments, 12-week-old (12 w) and 25-week-old (25 w)
KO mice were used, and these mice were euthanized at
20 weeks (20 w) and 29 weeks (29 w), respectively, for
biochemical and histological analyses.
Silva et al. Genetic Vaccines and Therapy 2012, 10:2 Page 3 of 11
http://www.gvt-journal.com/content/10/1/2MLV vectors, mesenchymal stem cell cultures and
transduction
The cDNAs encoding either human IDUA or GFP were
excised from pTIGER vectors (www.addgene.org) using
EcoRI and inserted into an EcoRI-digested pLXSN vector
(24). The resulting plasmids were designated MLV-IDUA
and MLV-GFP. The pLXSN vector has a retroviral long-
terminal repeat sequence (L), cloning site (X), internal
Simian virus 40 promoter (S) and neomycin-resistance
gene (N).
To obtain virus-producing cells, 5× 105 PT67 packaging
cells (Invitrogen) were transfected using calcium phosphate.
After 6 hours, the medium was replaced with fresh
medium, and the cells were cultured for an additional 48 h
in a humidified incubator at 37°C. The cultured cells were
split for G418 selection (1 mg/ml), and the virus-producing
clones were isolated using cloning rings for amplification.
The vectors were titrated using NIH3T3 cells and 8 μg/mL
of polybrene [24,25].
The viral vectors were collected from the supernatant
of each cell line and concentrated in a Sorvall centrifuge
(rotor SS34) at 16000 rpm for 2 hours [24,25]. For each
20 mL of viral vector, 4 mL of 20% sucrose in water was
added. After centrifugation, the supernatant was drained
off, and the pellet was resuspended in a volume of
serum-free DMEM, without antibiotics and glutamine,
and incubated overnight at 4°C. The G418 and cell-culture
reagents were purchased from Invitrogen (Burlington, ON,
Canada), and the protamine sulfate and polybrene were
purchased from Sigma (St Louis, MO, USA).
The MSC cultures were established from the bone
marrow of 8-week-old KO mice, as previously described
[26]. The MSCs were characterized using flow cytometry
and antibodies specific for CD29 and CD44 (for the
MSCs) and CD11b and CD45 (for the hematopoietic
cells) and by the ability of the cells to differentiate into
adipocytes and osteoblasts, following previously
described methods [27].
The MSCs were transduced at two different MOIs
(multiplicity of infection), always using 5 × 104 cells pla-
ted on 25 cm2 dishes. The transduction was conducted
for 24 hours in the presence of 10 μg/mL protamine
sulfate. The medium was then replaced, and the cells
were cultivated for 7 more days at 37°C in 5% CO2; the
resulting culture medium was used to determine the
IDUA activity. The MSC cultures demonstrating IDUA
activity were allowed to grow for an additional 3 days in
75 cm2 dishes and used for the in vivo experiments.
Cells at passage 3 and 4 were used for the in vivo
experiments.
For transduction of the NIH3T3 mouse fibroblast
cell line, the MSC transduction procedure was used.
After transduction, the cells were selected with G418
(1 mg/mL) for at least 15 days. To determine thetransduction efficiency of MSC with the gfp reporter
gene, GFP-positive cells were counted using a fluores-
cence microscope.
Alpha-L-iduronidase activity
Cells were collected after trypsinization, and the pellet
was resuspended in homogenization buffer (10 mM
NaPO4 pH 5.8, 0.1 mM DTT and 0.1% Triton X-100).
The IDUA dosage protocol is described in M. Camassola
et al. (submitted for publication). Briefly, in a 96-well
microplate, 10 μL of each sample was mixed with 10 μL
of 2.85 mM 4-methylumbelliferyl-alpha-L-iduronide
(4MU-I, Toronto Research Chemicals, North York, ON,
Canada) and 40 μL of 0.2 M formate buffer, pH 2.8. The
plate was incubated at 37°C for 1 h, and the reaction was
stopped by the addition of 175 μL of stop buffer (0.5 M
glycine-NaOH, pH 10.3). The fluorescence of the 4MU
product was determined using a Spectramax M2 fluor-
imeter (Molecular Devices, Sunnyvale, CA, USA) using
365 and 455 nm wavelengths for excitation and emission,
respectively. The protein concentration was determined
using the Bio-Rad protein dosage kit (Bio-Rad Laboratories,
Hercules, CA, USA). The IDUA activity is expressed in
units (U) representing nmols/h/mg of protein.
GAG measurement
One third of the brain tissue was cut, ground in 10
volumes of acetone and left to stand overnight at room
temperature. The acetone was changed every day over a
period of five days and then discarded, and the sample
was dried completely at 50°C. The dry weight was
recorded, and the sample was incubated with 4 mg/mL
maxatase in 0.05 M Tris–HCl buffer, pH 8.0, containing
0.15 M NaCl for 24 h at 60°C. Trichloroacetic acid was
added (10% of final volume), and the sample was allowed
to stand for 20 minutes at 4°C. The resulting precipitate
was removed by centrifugation at 5000 × g for 20 minutes
at room temperature. The GAGs from the supernatant
were precipitated with two volumes of ethanol. After
overnight incubation at −20°C, the GAGs were col-
lected via centrifugation, vacuum dried and treated with
deoxyribonuclease I (Sigma). The isolated GAGs were
analyzed via agarose gel electrophoresis, using purified
chondroitin sulfate (CS) and dermatan sulfate-heparan
sulfate (DS-HS) as standards [28]. The quantification of
the isolated GAGs was conducted using densitometry
and Quick Scan 2000 Software (Beaumont, TX, USA).
The results are expressed as μg/g of dry tissue or as the
percentage of individual GAGs.
Injection of transduced MSCs into the brain
This protocol was based on the study published by
Coulson-Thomas and collaborators [29]. IDUA KO
mice were anesthetized, and 1 × 106 MLV-MSCs in 5 μL
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of the brain using a 30-gauge needle. Five minutes after in-
jection, the needle was removed, and the incision was
sutured. Mice were left on a heating pad to recover and
then transferred into micro-isolators. At the end of the
experiments, the mice were euthanized, and the brains were
removed and divided in 3 parts. One part was used for gen-
omic DNA extraction, the second part was used for GAG
determination and the last part was immediately processed
with a Potter device (Eberbach Corporation, mod 7265.25,
Ann Arbor, MI, USA) in 1 mL of homogenization buffer to
determine the IDUA activity.Behavioral tests
All behavioral tests were conducted in the same room
with controlled temperature and luminosity. The mice
were separated into three groups, wild type (WT),
knockout (KO) and knockout mice treated with IDUA
KO MSCs transduced with MLV-IDUA (KO/IDUA).
Before and after gene therapy, the animals underwent
behavioral tests that focused on motor function and
anxiety. The elevated plus maze test was conducted as
previously described [16]. The mice were placed on a
plus maze that had two walled arms (30 × 5 × 15 cm)
and two open arms (30 × 5 cm) for 5 min. The spent
time freezing and grooming and the number of times
rearing and crossing (internal, external and total) were
measured.
The maze was elevated 50 cm from the floor, and
the animals were placed at the center to explore freely.
The number of entries was counted, and the time
spent in the closed or open arms was measured.
The open field test was performed based upon previ-
ous work [30] and is an observation of animals exposed
only once to a circular arena with a diameter of 50 cm
surrounded by a wall that is 40 cm high. The floor of
the arena was divided into 19 equal squares, and the
mice were placed at the center to explore freely. The
time spent freezing and grooming and the number of
times rearing and crossing (internal, external and total)
were measured. Nonparametric Mann–Whitney U tests
were used to compare the two variables. p values less
than 0.05 were considered statistically significant.Molecular analyses
Genomic DNA (gDNA) was extracted from the brain
using the QIAamp DNA Extraction Kit (QIAGEN, Hilden,
Germany). PCR reactions for IDUA and an endogenous
control were performed as previously described [30,31].
The PCR conditions used for IDUA detection were also
used to detect GFP using the primers 5′-gag cct ggg gac
ttt cca cac cc-3′ and 5′-gaa aat tgt gat gct att gc-3′.Immunohistochemistry
The animals were deeply anesthetized via an intraperito-
neal injection of a ketamine and xylazine and intracardially
perfused first with 0.9% saline solution and then with 4%
paraformaldehyde in 0.1 M PBS. The brains were removed
from the skull, fixed overnight at room temperature with
4% paraformaldehyde in 0.1 M PBS and cryoprotected
with 0.1 M PBS containing 30% sucrose. The brains were
frozen in isopentane (Sigma) using dry ice and embedded
in Tissue Tek (Electron Microscopy Sciences, Hatfield,
PA, USA). Midsagittal sections were cut with a cryostat
(20 μm thickness), mounted on siliconized glass slides
(DakoCytomation, São Paulo, Brazil) and fixed with 4%
paraformaldehyde for 1 h. After thoroughly washing
with PBS, the sections were first incubated with 0.1%
Triton X-100 in PBS for 1 h at room temperature and
then in blocking solution (10% BSA and 0.1% Triton
X-100 in PBS) for 1 h at room temperature. The sec-
tions were then incubated with a rabbit anti-GFP anti-
body (1:500, Molecular Probes/Invitrogen, Eugene, OR,
USA) overnight at 4°C. The next day, the sections were
washed three times for 5 min each with PBS, incubated
with DAPI (Molecular Probes/Invitrogen) and then incu-
bated with an AlexaFluor 488–conjugated goat anti-rabbit
antibody (1:200) in PBS for 1 h at room temperature. After
washing three times in PBS for 5 min each, the sections
were mounted with Fluormont-G (Electron Microscopy
Sciences) and analyzed with fluorescence microscopy
(Olympus BX60, Tokyo, Japan).Results
Characterization of the IDUA KO MSCs and the
transduction efficiency of the MLV vectors
The morphology of the MSCs isolated from the IDUA
KO mice was characteristic of murine MSCs (Figure 1A).
When exposed to inducing media, the MSCs differen-
tiated into adipocytes and osteoblasts, as determined
based on staining with Oil Red O and Alizarin Red, respect-
ively (Figure 1A). Flow cytometric analyses demonstrated
that the cells expressed surface markers characteristic of
MSCs, such as CD29 and CD44, and lacked the expression
of hematopoietic markers, such as CD11b and CD45
(Figure 1B).
To evaluate the transduction efficiency of the concen-
trated viral vectors, NIH3T3 cells were transduced at an
MOI of 5.2 and selected with G418, after which the IDUA
activity was evaluated (Table 1). These cells were used as a
control for IDUA activity because the MLV-derived vectors
have a high tropism for the NIH3T3 cell line, and these cells
can be selected with G418 to obtain 100% IDUA-positive
cells. Using these selected cells, we estimated the maximum
level of IDUA gene expression and evaluated IDUA gene
expression levels in the transduced MSCs.
Figure 1 Characterization of MSC cultures derived from IDUA KO mice. When cultured in differentiation-inducing media, the MSCs readily
differentiated into adipocytes (A-II) or osteoblasts (A-IV), as determined via staining with Oil Red O and Alizarin Red, respectively. Control cultures
stained with the same reagents (Oil Red O or Alizarin Red in A-I and A-III, respectively) demonstrate the adherent, fibroblastoid morphology that
characterizes the MSC cultures. The original magnification is 100×. As determined via immunophenotyping, the MSC cultures were negative for
CD11b and CD45 and positive for CD29 and CD44. The MSCs and control cells are shown in grey and white, respectively (B).
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blasts was at least 245 times lower than the activity in
G418-selected cells (23.8±5.8 U versus 5,849.1±851.6 U;
Table 1). The IDUA KO MSCs were transduced at an MOI
of 5.2 or 77 to compare the transduction rate. One week
after transduction, the cells transduced at an MOI of 77
presented a similar level of IDUA activity when compared
to the transduced and selected NIH3T3 cells. However,
after 4 weeks, production of IDUA by these cells decreased
to basal levels. By contrast, IDUA KO MSCs transduced at
an MOI of 5.2 had only 40% activity in the first week, and
after four weeks, IDUA production increased to 51%, reach-




IDUA (U) c GFP (%)d IDUA (U
Control ND NE ND
MLV-GFP NE NE 20.7 ± 21.
1w (I/G) 2278 ± 249 8.9 ± 1.3 5340.4 ± 1
3-4w (I/G) 3016.5 ± 780 9.3 ± 2.2 59.7 ± 16.
6w (I/G) 15 ± 1.4 ND NE
a MPSI-MSC were transduced with 5.2 or 77 MOI of MLV vectors and evaluated for t
vectors and selected with G418 (these cells were used as a positive control cells); N
in units of activity (nmols/h/mg of protein); d GFP-positive cells are expressed in per
monitor expression of IDUA or GFP, MSC were transduced with MLV-IDUA or MLV-Gcells also stopped producing IDUA, achieving just 15 U.
The MSCs transduced with the MLV-GFP vector, which
expressed only GFP and was used to determine the trans-
duction rates, appeared to produce some level of IDUA
(Table 1). However, this basal and non-specific activity
could be due to the interference of GFP fluorescence, which
emits a weak light signal at 455 nm.
The transduction rates, as determined by GFP expression,
were similar to those of cells transduced with the MLV-
IDUA vector (Table 1). G418-selected NIH3T3-GFP cells
were 100% positive for GFP; whereas, one week after trans-
duction, the IDUA KO MSCs transduced at an MOI of 5.2
or 77 MOI were only 8.9% and 21.3% GFP positive,of MPSI-MSC and NIH3T3 cells with MLV-IDUA (I) and
NIH3T3b
MOI 77 G418
)c GFP (%)d IDUA (U)c GFP (%)d
NE 23.8 ± 5.8 0
6 NE 29.5 ± 29.5 100
37.0 21.3 ± 6.6 NE NE
8 ND 5849.1 ± 851.6 100
ND NE NE
ransgene expression during 6 weeks; b NIH3T3 cells were transduced with MLV
D = non detectable; NE = non-evaluated; w = week; c IDUA activity is expressed
centage. All experiments were performed at least in duplicates. (I/G) means to
FP, respectively.
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MOI of 77 had no remaining GFP-positive cells, whereas
the cells transduced at an MOI of 5.2 maintained the same
percentage of GFP-positive cells that was detected 1 week
after transduction. Six weeks after transduction, however,
there were no detectable GFP-positive cells in the MSC cul-
tures transduced at an MOI of 5.2, similar to the observed
lack of IDUA activity in the cultures transduced with MLV-
IDUA.
The MLV-IDUA-transduced MSCs were stained with
toluidine blue to analyze vacuoles. The vacuole size of
the treated cells was smaller than that of the non-treated
cells, demonstrating some recovery of lysosomal function
following the expression of the IDUA transgene
(Figure 2).
Behavioral evaluation
The WT and KO mice were tested in the open field and
elevated plus maze tests before (Table 2) and after geneFigure 2 Characterization of the vacuole size of MSCs
transduced with MLV-IDUA by toluidine blue staining. The
arrows indicate the representative vacuoles for each group. The
MSCs from the KO mice (KO) show many large vacuoles, while the
MSCs transduced with MLV-IDUA (TR) show small vacuoles.therapy (Table 3) to compare the exploratory behavior
among the groups. In the open field test, the total num-
ber of events counted (total square) in younger WT mice
(215.6) was much higher than the number in older WT
mice (123), indicating hyperactivity in the younger mice.
A similar profile of events was also observed in younger
(157.2) and older (104.7) IDUA KO mice, but with lower
overall frequencies than the number observed in the WT
mice (Table 2). These results allow for the clear differen-
tiation of young and old mice, as well as WT and IDUA
KO mice. There were no significant variations in the
freezing, grooming or rearing activities at these time
points.
Upon aging (to 29 weeks), the WT mice became less
active (TS = 62.3), and the KO mice became even less ac-
tive (TS = 32.2); however, the treated mice reached activ-
ity values similar to those for WT mice (TS = 72). The
rearing activity of 29-week-old IDUA KO mice was
decreased (1.7) when compared with WT mice (6.7) but
was significantly improved after treatment (11). These
results demonstrate a significant improvement in loco-
motive activity following gene therapy (Table 3).
In the elevated plus maze test, the WT mice showed
the natural tendency of rodents to spend more time in
the closed arm than the open arm. With older mice, this
behavior is more evident; older mice spent 182 s in the
closed arm and 223.2 s with younger mice. A similar
profile was also observed with the number of entries into
the arms (Table 2). These results were validated by the
results of the opened-arm tendencies, which are approxi-
mately the inverse of those indicated by the closed-arm
data. The KO mice displayed a behavior similar to that
of young WT mice, spending more time in the closed
arm ( 193 s) irrespective of age; however, at 29 weeks
of age, the KO mice appeared very sick and spent most
of their time in the closed arm (CA=93.5 s). Surpris-
ingly, the KO mice treated with gene therapy had a mo-
bility similar to that of WT mice (CA= 286 s), even at
29 weeks (CA= 283 s) (Table 3).
GAG Deposition
At the end of the behavioral evaluations, the animals
were euthanized, and the brains were removed for cellu-
lar and molecular analyses. IDUA activity was undetect-
able in any of the animals. PCR amplification of the
IDUA sequence from genomic DNA showed the pres-
ence of the expected DNA fragment in almost all treated
mice, except for four samples (Figure 3).
Increased GAG deposition was visible in the KO mice
when compared with the WT mice, and GAG deposition
increased with age (Figure 4 and Table 4): from 1566 in
WT at 20 w and 1907 in WT at 29 w to 2443 in KO at
20 w and 3234 in KO at 29 w. The treatment with
IDUA-expressing MSCs in young mice resulted in
Table 2 Open field and elevated plus maze tests performed before applying gene therapy
Open Field Elevated plus maze
Freezing (s) Grooming (s) Rearing (#) IS (#) ES (#) TS (#) OA (#) OA (s) CA (#) CA (s)
12 week-old mice
WT (n= 5) mean 9.4 10.4 46.4 79 136.6 215.6 2.8 29 9.2 223.2
SD 5 6.7 10.8 22 25.3 44.8 1.5 24.9 3.3 23.4
KO (n= 10) mean 15.1 12.1 32.2 42.5 114.7 157.2 2.8 42.9 6.4 194.5
SD 9.6 6.7 14.1 14.3 38.5 42.6 2.8 47.4 4.3 60.2
p <0.05 p< 0.05
25 week-old mice
WT (n= 3) mean 25.3 10 37.3 49 74 123 2.3 55.3 8.3 182
SD 15.9 4 24.1 34.7 15.9 50.4 0.6 64.7 5.7 113.6
KO (n= 5) mean 24.4 9.1 23.7 33.9 70.9 104.7 2.6 25.9 4.5 193
SD 10 6 13 13.6 38 46.4 3.1 25.9 3.0 49.4
# = number of events; s = seconds; SD = standard deviation; IS = internal square; ES = external square; TS = total square; OA = open arm;
CA = closed arm; WT = wild-type; KO = IDUA knock-out.
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similar to the level observed in WT mice at 29 w. In
treated older KO mice, the decrease was more significant
(1509), reaching a level similar to the level in the
younger WT mice at 20 w. Despite the dramatic reduc-
tion in total GAG deposition following gene therapy, the
proportion of dermatan and heparan sulfate in the total
GAG content in the KO mice did not change signifi-
cantly after treatment and remained higher than level
observed in the WT mice.
MSC migration
To evaluate the migration of the injected MSCs in the
brain, cells transduced with the MLV vector carryingTable 3 Open field and elevated plus maze tests performed a
Open Field
Freezing (s) Grooming (s) Rearing (#)
20 week-old mice
WT (n= 4) mean 8.8 8 12.3
SD 7.8 7.3 5.8
KO (n= 3) mean 5,0 6,7 14,3
SD 4,0 7,2 11,6
KO/IDUA (5) mean 8.6 9.2 16.2
SD 9.6 2.8 6.5
29 week-old mice
WT (n= 3) mean 8.7 9.3 6.7
SD 5.5 8.1 3.8
KO (n= 4) mean 5.0 5.2 1.7
SD 2.9 4.1 2.4
KO/IDUA (3) mean 5.7 5.7 11
SD 2.1 2.1 14.2
# = number of events; s = seconds; SD = standard deviation; IS = internal square; ES
CA = closed arm; WT = wild-type; KO = IDUA knock-out.GFP were injected into the brain following the same
procedure. The presence of MSCs in the brain ventri-
cles is clearly detected after one week. However, even
though the cells were injected into the left ventricle,
GFP-positive cells were detected in all of the ventricles
(Figure 5), demonstrating the mobility of these cells in
the ventricles.
Discussion
In gene therapy studies, the characterization of the level
and time of gene expression for each vector is the first
and fundamental step for the validation of the studies
because these factors depend on the promoter/enhancer
used for vector construction, the vector formulation, thefter applying gene therapy
Elevated plus maze
IS (#) ES (#) TS (#) OA (#) OA (s) CA (#) CA (s)
28.5 86.5 115 1.5 38.3 4.3 170.3
8.7 23.5 28.6 1.9 72.6 2.1 135.7
10,7 39,0 49,7 0,7 3,3 3,0 231,7
10,0 7,5 16,1 0,6 3,1 1,0 40,8
29.4 77.8 107.2 1 11.2 5.2 270.8
4 29 31.8 0.7 8.8 4.5 19.9
17 45.3 62.3 0.3 1.7 2.7 286
5.3 27.6 32.9 0.6 2.9 1.5 3.5
8.7 23.5 32.2 1.2 93.5 1.5 93.5
7.6 11.4 18.0 1.3 130.2 1.3 124.5
16 56 72 0.7 4 3.3 283
13.1 45.2 58.3 1.2 6.9 2.1 14.2
= external square; TS = total square; OA = open arm;
Figure 3 PCR analysis of transduced MSCs and treated mice. Genomic DNA isolated from MSCs from KO mice (A), brains from untreated KO
mice (B), brains from wild-type mice (C), and brains from KO mice treated with MLV-IDUA-transduced MSCs (D) was used to analyze the IDUA and
β-actin genes. The three molecular markers in the figures represent 300, 200 and 100 bp. N= PCR negative control; P = PCR positive control;
I = IDUA; En = Endogenous β-actin; NT = non-transduced cells. The numbers on the figures indicate the number of each animal.
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tion route. Previous work has demonstrated that human
MSCs are poorly transduced with MLV vectors [32]; con-
sequently, a high MOI is used to increase the transduc-
tion efficiency, with the expectation of a high-level gene
expression. To estimate the MOI necessary to obtain a
high level of IDUA gene expression, MSCs were infected
at two MOI and compared with NIH3T3 cells trans-
duced with the same vector and selected with G418 to
obtain 100% genetically modified cells. An MOI of 77
resulted in a transduction efficiency of 21%. However,
curiously, this percentage was sufficient to reach the
level of IDUA produced by the selected NIH3T3 cells
(Table 1), suggesting a higher production of IDUA per
cell in the MSCs when compared with NIH3T3 cells.
Additionally, an MOI of 5.2 resulted in a transduction ef-
ficiency of 10%, and the transduced MSCs produced ap-
proximately 50% of the IDUA when compared with the
cells transduced at an MOI of 77. These results indicate
that the concentration of virus required to increase the
transduction efficiency is not linear and that the level ofFigure 4 Electrophoretic analysis of GAGs extracted from the brains o
from mouse brains were separated via electrophoresis to identify chondroi
GAG was quantified by densitometry. The total GAG amount is expressed a
number (#) and percentage of CS are indicated in the figure. The arrows in
electrophoresis.IDUA gene expression per cell is highly variable among
different cell types.
As we aimed to use long-term gene expression to cor-
rect a permanent IDUA deficiency in our study, the
MLV-transduced MSCs were monitored for more than a
month by measuring IDUA activity as well as by count-
ing the number of GFP-positive cells. The IDUA activity
in MSCs transduced at an MOI of 77 decreased to the
basal level in 4 weeks, and this result was confirmed by
the absence of GFP-positive cells at this time. However,
the MSCs transduced at an MOI of 5.2 maintained
transgene expression two weeks longer than the MSCs
transduced at the higher MOI, as verified both by the
IDUA activity and the presence of GFP-positive cells. Si-
lencing of gene expression after MLV transduction is a
phenomenon that is known, especially in progenitor cells
[33-35]. Our results indicate that this silencing is accen-
tuated at higher MOI. Even though the MSCs transduced
at the higher MOI produced twice the amount of IDUA
when compared with the cells transduced at the lower
MOI, we decided to use the lower MOI in the remainingf 20- and 29-week-old IDUA KO and WT mice. The GAGs extracted
tin (CS) and dermatan (DS)-heparan (HS) sulfate, and the band of each
s μg/g of dry tissue. The phenotype, age group, animal identification
dicate the direction of movement of the GAG sample during gel
Table 4 GAG concentration in brains of mice treated with
gene therapy
# Groups Total GAG Mean±SD DS-HS (%)a
11 WT 20w 1140.4 1566 ± 419 6.2
12 WT 20w 1281.2 9.9
13 WT 20w 1997.3 32.1
14 WT 20w 1849.6 29.0
1 WT 29w NE 1907± 212 23.8
2 WT 29w 2057.0 NE
3 WT 29w 1757.3 9.8
15 KO 20w 2741.0 2443 ± 470 40.0
16 KO 20w 2889.3 48.8
24 KO 20w 1850.0 50.0
25 KO 20w 2290.0 48.2
4 KO 29w 4345.0 3234 ± 1287 49.8
5 KO 29w 3235.5 47.7
26 KO 29w 1429.0 43.5
27 KO 29w 3930.0 57.3
19 KO/IDUA 20w 1220.2 2065 ± 487 37.3
20 KO/IDUA 20w 2323.0 42.1
21 KO/IDUA 20w 2404.4 46.1
22 KO/IDUA 20w 2296.0 49.2
23 KO/IDUA 20w 2083.0 49.4
8 KO/IDUA 29w 1656.0 1509 ± 364 42.6
9 KO/IDUA 29w 1778.9 39.8
10 KO/IDUA 29w 1094.2 55.6
Total GAG is expressed in μg/g dry tissue; (#) Animal identification number;
a % = [DS-HS]/[Total GAG] * 100; NE = non-evaluated; w = week-old.
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long-term gene expression.
The main goal of our gene therapy study was to reduce
GAG deposition in the brain after the ventricular injec-
tion of MSCs transduced with MLV-IDUA; we expected
an improvement in exploration as a consequence of the
gene therapy. The injection of the MSCs was not difficult
and was reproducible, even in mice weighing 20–25 g,
and the mortality caused by the injection procedure was
low. A single injection of MSCs in the left ventricle was
enough to distribute these cells evenly in all ventricular
areas (Figure 5), which is a very important experimental
finding that can be used for translation to a clinical assay
in the future.
In our study, we used adult mice because MPSI path-
ology is already established in adults, and therefore, these
mice mimic the situations observed in human patients.
To validate our study, the behavioral characteristics were
initially analyzed. As neurodegeneration is a progressive
and slow process that affects animal behavior, there is no
specific age at which the animal can be diagnosed as fully
affected. Therefore, it is very important to determine thebehavioral state of KO animals before initiating gene
therapy experiments. To evaluate the evolution of MPSI
disease and aging, two behavioral tests were used in our
study, the open field and elevated plus maze tests, which
monitor exploratory activity and anxiety, respectively. In
this study, the hyperactivity of young WT mice was
clearly observed in the open field test, with measure-
ments of 215.6 events in total squares that decreased to
123 events with age (Table 2). In KO mice, reduced
movement was evident when compared with WT mice,
and the movement decreased further with age. A similar
reduction was observed in rearing behavior in both the
old and KO mice. These results indicate that exploratory
activity, which requires good neuromuscular function, is
dependent on age and MPSI disease progression. How-
ever, the anxiety and cognitive levels, as determined via
the elevated plus maze test, seemed to be less affected in
younger KO mice (CA= 231.7 s) but strongly affected in
older KO mice (CA= 93.5 s) (Table 3). These findings
suggest that MPSI somehow initially affects neuromotor
activity more than the activity of the central nervous sys-
tem. These results also demonstrate that sick IDUA KO
mice can be easily identified via the open field and the
elevated plus maze tests, which should be considered im-
portant tests for monitoring the evolution of this disease
and the efficacy of gene therapy treatments.
Ex vivo transfer of IDUA via the injection of transduced
MSCs directly into the brain resulted in a clear improve-
ment in the behavioral tests: the treated mice behaved
like age-matched WT in both the open field and elevated
plus maze tests (Table 3). The older treated mice were
29 weeks old at the time of the test, and at this age, most
sick mice become very weak; some die because of the
advanced illness. Therefore, the behavioral improve-
ments detected in our study are highly relevant because
the treated mice behaved like WT mice, even at an
advanced age.
To understand the observed behavioral improvements,
GAG deposition in the brain was analyzed. One possible
mechanism underlying the neuropathological progression
in these animals, and in IDUA patients, is the progressive
accumulation of GAGs, which occurs due to the lack of
IDUA activity [5]. The IDUA KO mice normally present
with approximately 60% more GAGs when compared with
WT mice (1566 μg to 2443 μg for 20-week-old mice and
1907 μg to 3232 μg for 29-week-old mice); however, the
treated young mice displayed an intermediate level of
GAGs, which can explain the improved behavioral perform-
ance. In the older treated KO mice, the reduction in GAG
deposition was more drastic, reaching the lowest observed
level (1509 μg). Once again, the reduced GAG deposition
likely underlies the improved behavioral performance
(Table 4). Collectively, these data demonstrate a strong rela-
tionship between GAG accumulation in the brain and
Figure 5 Immunohistochemistry of mouse brains injected with GFP-expressing MSCs. The MSCs transduced with MLV-GFP were injected
into mouse brains and analyzed via IHC 1 week later. Images of the right ventricle (RLV), the left ventricle (LLV) and the middle ventricular area are
shown.
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tration of MSCs expressing IDUA directly into the brain.
Importantly, this improvement can be seen even in
advanced disease.
The reduction in GAG deposition suggests the presence
of IDUA activity; however, enzymatic activity was not
detected in the brains of the treated mice. This is some-
what expected as in the in vitro study, IDUA activity was
detected up to 4 weeks after transduction of MSCs with
MLV-IDUA, and no activity was observed 6 weeks after
transduction (Table 1). As the injected MSCs are in a dif-
ferent environment, transgene expression can be shut
down early, and the MSC survival time could be shorter.
Therefore, the reduction in GAG deposition observed 1 or
2 months after injection of IDUA-expressing MSCs is
likely the consequence of high IDUA production at the be-
ginning of the treatment, which has an unknown duration.
As was previously discussed, ERP and bone marrow
transplantation do not slow neurodegeneration in MPSI
patients. Consequently, in our opinion, direct treatment of
the brain is necessary. With the present study, we demon-
strate that IDUA-expressing MSCs are a good therapeutic
candidate to treat neurodegeneration via direct injection
into the brain ventricles. This procedure can be performed
in MPSI patients by applying these cells via the cannula
used to drain liquid from the brain of these patients.Competing interests
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